Stuart Therapeutics Spotlights Topical RP Program - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Stuart Therapeutics Spotlights Topical RP Program

At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.

  • By

  • Eric Schlumpf

  • July 15, 2026

  • 2 min

Share

Clinical Scorecard: Stuart Therapeutics Spotlights Topical RP Program

At a Glance

CategoryDetail
ConditionRetinitis Pigmentosa
Key MechanismsNeuroprotective effect, reduction of inflammation, improvement of posterior retina health
Target PopulationPatients with retinitis pigmentosa, including younger individuals
Care SettingPreclinical development

Key Highlights

  • Collagen mimetic peptide platform for retinitis pigmentosa
  • Topical therapy designed for excellent safety profile
  • Preclinical studies show drop penetration throughout the posterior retina
  • Targets critical retinal extracellular matrix region
  • Potential for treating inherited retinal disease

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Individuals with retinitis pigmentosa

          Topical therapy with potential neuroprotective effects

          Clinical Best Practices

            Related Resources & Content

              Original Source(s)

              Stuart Therapeutics Spotlights Topical RP Program

              • by Eric Schlumpf

              • July 15, 2026

              Related Content

              GLP-1 Eye Effects Raise Questions

              Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

              Glycemic variability may signal retinal changes

              Greater glucose fluctuations but not HbA1c were associated with neuroretinal alterations over 3 years in pediatric patients with type 1 diabetes.

              Retinal Age as Disease Biomarker

              Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

              • May 27, 2026

              • 3 min